Recent Research Analysts’ Ratings Updates for TScan Therapeutics (TCRX)

A number of firms have modified their ratings and price targets on shares of TScan Therapeutics (NASDAQ: TCRX) recently:

• 12/23/2024 – TScan Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.
• 12/11/2024 – TScan Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
• 12/11/2024 – TScan Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
• 12/10/2024 – TScan Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $7.00 price target on the stock, down previously from $10.00.
• 11/15/2024 – TScan Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
• 11/12/2024 – TScan Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
• 11/6/2024 – TScan Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
• 11/5/2024 – TScan Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $10.00 price target on the stock.

TScan Therapeutics Price Performance

Shares of TCRX opened at $3.01 on Tuesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. The firm has a market cap of $160.65 million, a PE ratio of -2.84 and a beta of 0.79. The firm’s 50 day moving average price is $4.57 and its 200 day moving average price is $5.64. TScan Therapeutics, Inc. has a twelve month low of $2.60 and a twelve month high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.03. The business had revenue of $1.05 million for the quarter, compared to the consensus estimate of $2.86 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. As a group, research analysts expect that TScan Therapeutics, Inc. will post -1.12 EPS for the current fiscal year.

Institutional Investors Weigh In On TScan Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP bought a new position in TScan Therapeutics in the 2nd quarter worth $70,000. SG Americas Securities LLC acquired a new stake in shares of TScan Therapeutics in the third quarter valued at about $78,000. The Manufacturers Life Insurance Company bought a new position in shares of TScan Therapeutics in the second quarter worth about $90,000. XTX Topco Ltd bought a new position in shares of TScan Therapeutics in the third quarter worth about $112,000. Finally, MetLife Investment Management LLC lifted its position in shares of TScan Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock worth $116,000 after purchasing an additional 13,164 shares during the last quarter. 82.83% of the stock is currently owned by institutional investors and hedge funds.

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.